BABila Hassan Ali

Bila Hassan Ali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bila Hassan Ali has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phytochemical Constituents from Globimetula oreophila as Plasmepsin I and II Inhibitors in Antimalarial Drug Discovery: An In Silico Approach

    by Dauda Garba, Bila Hassan Ali, Bashar Bawa, Abdullahi Maryam, Hamza Asmau Nasiru, Yahaya Mohammed Sani, Muhammad Garba Magaji, Musa Isma’il Abdullahi, Aliyu Muhammad Musa, Hassan Halimatu Sadiya

    Malaria remains a critical global health challenge, particularly affecting Sub-Saharan Africa. Plasmepsins, vital in hydrolyzing peptide bonds within proteins, present promising targets for antimalarial drugs. Plasmepsins I and II, key aspartic proteases, are crucial in various parasite processes. This study investigates the inhibitory properties of quercetin, quercetrin, dihydrostilbene, 4′-methoxy-isoliquiritigenin, and stigmasterol from Globimetula oreophila on plasmepsins through in silico techniques, including ADME predictions and molecular docking. Results reveal strong interactions of these compounds with active site residues, with quercetrin and stigmasterol displaying notable binding affinities. These findings suggest the potential of G. oreophila metabolites as potent plasmepsin inhibitors, offering prospects for malaria treatment and prevention.


  • Open Access

    Exploring the Antimalarial Efficacy of Globimetula oreophila Leaf Fractions in Plasmodium berghei-Infected Mice: In Vivo Approach

    by Dauda Garba, Bila Hassan Ali, Bashar Bawa, Abdulrazaq Sanusi, Yahaya Mohammed Sani, Muhammad Garba Magaji, Musa Isma’il Abdullahi, Aliyu Muhammad Musa, Hassan Halimatu Sadiya

    The development of parasite resistance to first-line antimalarial medicines, especially the Artemisinin-based combination therapies (ACTs), has made the research and development of novel antimalarial medications vital. Globimetula oreophila, a plant used in traditional medicine to treat malaria, is a natural product that may provide new antimalarial drugs with fewer side effects, greater efficacy and lower risk of resistance than synthetic drugs. This study aims to evaluate the antiplasmodial properties of G. oreophila's fractions. The plant leaves were air-dried and reduced in size using a pestle and mortar. The pulverized plant was macerated in 70% ethanol and fractionated with solvent in increasing polarity of n-hexane, chloroform, ethyl acetate, and n-butanol to produce the various fractions. The antiplasmodial activity of the n-hexane, chloroform, ethyl acetate, and n-butanol fractions of G. oreophila leaf extract was assessed using an in vivo method in Plasmodium berghei-infected mice via prophylactic, suppressive, and curative test. The fractions' median lethal dose (LD50) was estimated to be greater than 5000 mg/kg in mice. The median effective dose (ED50) of the fractions at doses of 125, 250, and 500 mg/kg produced a significant (p<0.001) decrease in the level of parasitemia. The ethyl acetate fraction had the best antiplasmodium activity compared to other plant fractions. The fractions of G. oreophila showed significant in vivo antiplasmodial activity, which upholds the earlier in vivo findings for the crude extract and its folkloric use. Further study should be carried out to isolate active secondary metabolites responsible for this observed antimalarial activity in all four investigated fractions.


  • Open Access

    Therapeutic Potential of Fractions of Globimetula oreophila (Oliv. ex Hook.f.) Leaf Extract Growing on Azadirachta indica against Plasmodium berghei-Infected Mice: An In Vivo Approach

    by Dauda Garba, Bila Hassan Ali, Bashar Bawa, Abdulrazaq Sanusi, Yahaya Mohammed Sani, Musa Isma’il Abdullahi, Muhammad Garba Magaji, Aliyu Muhammad Musa, Hassan Halimatu Sadiya

    The development of parasite resistance to first-line antimalarial medicines, especially the ACTs, has made the research and development of novel antimalarial medications vital